Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the Necessity for Cycloplegia During Refraction of Chinese Children Between 4 and 10 Years Old.

Journal of pediatric ophthalmology and strabismus·2020
Same author

Forensic applicability of autosomal insertion/deletion loci in Chinese Daur ethnic group and genetic affinity evaluations between Daur group and reference populations.

Legal medicine (Tokyo, Japan)·2020
Same author

Dental caries experience and related risk indicators of 12-year-old students in Jilin, China.

Medicine·2020
Same author

The role of NAC transcription factor in plant cold response.

Plant signaling & behavior·2020
Same author

Monocyte-Derived Leukemia-Associated Macrophages Facilitate Extramedullary Distribution of T-cell Acute Lymphoblastic Leukemia Cells.

Cancer research·2020
Same author

An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway.

Cancer gene therapy·2020

Related Experiment Video

Updated: May 5, 2026

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

13.1K

7,8-dihydroxyflavone ameliorates scopolamine-induced Alzheimer-like pathologic dysfunction.

Chong Chen1, Xiao-Hong Li, Sai Zhang

  • 11 Institute of Traumatic Brain Injury and Neurology, Pingjin Hospital, Logistics University of Chinese People's Armed Police Forces , Tianjin, China .

Rejuvenation Research
|December 12, 2013
PubMed
Summary

7,8-dihydroxyflavone (7,8-DHF) protects against scopolamine-induced Alzheimer's disease (AD) symptoms in rats. This compound reversed amyloid-beta deposition, oxidative stress, and cognitive deficits, suggesting its therapeutic potential for AD.

More Related Videos

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

11.1K
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

42.5K

Related Experiment Videos

Last Updated: May 5, 2026

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

13.1K
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

11.1K
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

42.5K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Scopolamine (Sco) administration induces Alzheimer's disease (AD)-like pathology, including amyloid-beta (Aβ) deposition, oxidative stress, synaptic dysfunction, and cognitive impairment.
  • Alzheimer's disease is a prevalent form of dementia affecting millions worldwide, necessitating research into effective therapeutic interventions.

Purpose of the Study:

  • To investigate the neuroprotective effects of 7,8-dihydroxyflavone (7,8-DHF) against scopolamine-induced AD-like pathological changes and cognitive deficits in a rat model.
  • To evaluate whether 7,8-DHF can mitigate Aβ deposition, oxidative stress, and synaptic dysfunction caused by scopolamine.

Main Methods:

  • Rats were divided into four groups: control, scopolamine-induced (Sco), Sco + 7,8-DHF, and 7,8-DHF only.
  • Treatment involved daily intraperitoneal injections of scopolamine (1 mg/kg) and/or 7,8-dihydroxyflavone (1 mg/kg) over a period of 2-4 weeks.
  • Assessment included evaluating Aβ deposition, oxidative stress markers, synaptic function, and cognitive performance.

Main Results:

  • 7,8-dihydroxyflavone administration significantly reversed scopolamine-induced amyloid-beta deposition.
  • 7,8-DHF treatment effectively attenuated oxidative stress and synaptic dysfunction in the scopolamine-treated rats.
  • Cognitive deficits, including learning and memory impairments, were significantly improved by 7,8-DHF supplementation.

Conclusions:

  • 7,8-dihydroxyflavone demonstrates significant neuroprotective effects against scopolamine-induced Alzheimer's disease-like pathology.
  • 7,8-DHF shows promise as a potential therapeutic agent for mitigating the cognitive decline and neuropathological features associated with Alzheimer's disease.
  • Further research is warranted to explore the clinical applicability of 7,8-DHF in Alzheimer's disease treatment.